Stock Grabbing Investor’s Attention: Kite Pharma, Inc. (KITE)

The shares of Kite Pharma, Inc. (NASDAQ:KITE) currently has mean rating of 1.54 while 6 analysts have recommended the shares as “BUY”, 7 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 4.86M by 12 analysts. The means estimate of sales for the year ending Dec-16 is 19.57M by 13 analysts.

The mean price target for the shares of Kite Pharma, Inc. (KITE) is at 75.25 while the highest price target suggested by the analysts is 88.00 and low price target is 61.00. The mean price target is calculated keeping in view the consensus of 12 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Kite Pharma, Inc. (KITE) stands at -1.21 while the EPS for the current year is fixed at -5.60 by 14 analysts.

The next one year’s EPS estimate is set at -5.06 by 14 analysts while a year ago the analysts suggested the company’s EPS at -5.60.

In its latest quarter ended on 31^st March 2016, Kite Pharma, Inc. (KITE) reported earnings of $-0.90. The posted earnings topped the analyst’s consensus by $0.18 with the surprise factor of 16.70%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 8, 2016 Kite Pharma, Inc. (KITE) announced three oral presentations relating to its clinical programs will be delivered at the upcoming 2016 European Hematology Association (EHA) Annual Congress in Copenhagen, Denmark, June 9-12, 2016.

“We are excited to showcase the progress we have made with personalized T-cell immuno-oncology for people with refractory lymphoma and to share our understanding of the outcomes for this patient population who have limited or no treatment options,” said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. “These data are important to advance our novel breakthrough personalized treatments and ultimately address critical unmet medical needs.”